MBX Biosciences, a clinical-stage biopharmaceutical company, has recently released its 10-K report, revealing a focus on the discovery and development of precision peptide therapies for endocrine and metabolic disorders. The company's lead product candidate, MBX 2109, is in a Phase 2 clinical trial for the treatment of chronic hypoparathyroidism, while MBX 1416 and MBX 4291 are in Phase 1 clinical trials for potential therapies for post-bariatric hypoglycemia and obesity, respectively. MBX Biosciences was founded in 2018 and is based in Carmel, Indiana.
The 10-K report also provides insight into MBX Biosciences' financial condition and results of operations. The company reported net losses of $87.0 million and $61.9 million for the years ended December 31, 2025, and 2024, respectively. As of December 31, 2025, MBX Biosciences had cash, cash equivalents, and marketable securities totaling $373.7 million. The report also outlines the company's efforts to raise capital, including completing an initial public offering in September 2024 and an underwritten public offering in September 2025, which generated approximately $187.4 million in net proceeds.
Additionally, the report provides details about MBX Biosciences' Exclusive License Agreement with Indiana University Research and Technology Corporation (IURTC), granting the company an exclusive, royalty-bearing license to certain IURTC patent rights for the development of new product candidates. As part of the agreement, MBX Biosciences agreed to pay royalties based on net sales, an annual maintenance fee, and milestone payments in the event of successful achievement of specified development milestones.
Today the company's shares have moved -0.93% to a price of $40.53. For the full picture, make sure to review MBX Biosciences's 10-K report.
